()
 
 

Overview

Alexza is an emerging pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. The Company has six product candidates in development; AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic patients, AZ-002 (Staccato alprazolam) for the acute treatment of panic attack associated with panic disorder, AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches, AZ-003 (Staccato fentanyl) ...


Contact Information

1020 East Meadow Circle
Palo Alto, CA 94303

tel: 650-687-3900
fax: 650-687-3999
http://www.alexza.com

,  



Investor Relations



tel:
fax:




Stock

Exchange: NASDAQ
Industry: Drug Manufacturers - Other
Market Cap: $178.5M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.